UP!

ARNA $69.25   View long term graphs

Arena Pharmaceuticals
Type
Public (NASDAQ: ARNA)
Industry Biotechnology
Founded 1997
Headquarters San Diego, California, U.S.
Key people

Jack Lief, cofounder
Dominic Behan, co-founder and senior scientist
Amit Munshi, CEO
Kevin Lind, CFO
Products Belviq
Revenue IncreaseUS$27,600,000 (FY 2012)
Operating income
DecreaseUS$−57,000,000 (FY 2012)
Net income
DecreaseUS$−85,500,000 (FY 2012)
Total assets IncreaseUS$261,000,000 (FY 2012)
Total equity IncreaseUS$98,600,000 (FY 2012)
Website www.arenapharm.com

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease. In 2016 the company downsized and shifted its focus to developing new drugs currently being tested in clinical trials.

Arena Pharmaceuticals Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. Arena focused on discovering drugs that act on G protein-coupled receptors (GPCRs). The company developed technology it called Constitutively Activated Receptor Technology (CART) that identified drug leads targeting GPCRs and other classes of receptors to. CART was used to identify drug leads able to act as receptor inhibitors to decrease a biological response or act as receptor activators to increase a biological response.

The company has one drug on the market, Belviq (lorcaserin), a weight-loss medication. The U.S. Food and Drug Administration (FDA) approved lorcaserin on June 27, 2012. The company commtitted to a sales force commitment of 200. Lorcaserin is approved for use in adults with a body mass index (BMI) of 30 or greater, which is considered obese, or adults with a BMI of 27 or greater and who have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol. However, sales of Belviq were disappointing. In 2015 the company laid off 80 workers; this was followed in July 2016 by the layoff of another 100 employees (approximately 73% of remaining workforce). In January 2017 Arena announced that it is selling Belviq to its Japanese partner, Eisai Co. Ltd., which will manufacture and market the drug; Arena will draw a royalty on global sales.

The sale completes a pivot in emphasis toward drugs still under development. Drugs in the company's pipeline includes medications designed to treat pain, ulcerative colitis and pulmonary arterial hypertension. As of September 2014, potential products that had not yet been approved by the FDA included Temanogrel (thrombotic diseases), Ralinepag (pulmorary arterial hypertension), APD334 (autoimmune disease), APD371 (pain), and Nelotanserin.

News

Arena Pharmaceuticals, Inc. 3.07% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-02-24 Future report Set alerts
Q3 2020 2020-11-05 Future report Set alerts
Q2 2020 2020-08-05 -1.61 -1.61
Q1 2020 2020-05-07 -2.00 -2.00
Q4 2019 2020-02-26 -1.76 -1.76
Q3 2019 2019-11-07 -1.46 -1.46
Q2 2019 2019-08-07 -1.24 -1.24
Q1 2019 2019-05-08 12.10 12.10
Q4 2018 2019-02-26 1.35 1.35
Q3 2018 2018-11-07 -0.70 -0.70

Ratings

2016-05-10 Reiterated Rating Wells Fargo Hold
2016-05-10 Reiterated Rating Wells Fargo & Co. Hold
2016-03-02 Reiterated Rating Piper Jaffray Buy
2016-03-02 Reiterated Rating Piper Jaffray Cos. Buy
2016-03-01 Reiterated Rating RBC Capital Sector Perform $2.00 to $1.50
2016-03-01 Reiterated Rating Royal Bank Of Canada Sector Perform $2.00 to $1.50
2016-01-27 Reiterated Rating Needham & Company LLC Hold
2015-11-11 Reiterated Rating Needham & Company LLC Hold
2015-11-11 Lower Price Target RBC Capital Sector Perform $5.00 to $2.00
2015-10-30 Reiterated Rating Needham & Company LLC Hold
2015-10-28 Lower Price Target WallachBeth Capital Buy $6.00 to $4.00
2015-05-14 Reiterated Rating BMO Capital Markets Market Perform $9.00
2015-05-13 Reiterated Rating Needham & Company LLC Hold
2015-05-12 Lower Price Target WallachBeth Capital Buy $8.00 to $6.00
2015-02-02 Reiterated Rating Piper Jaffray Overweight $7.50
2015-01-22 Initiated Coverage RBC Capital Sector Perform $5.00
2015-01-07 Reiterated Rating BMO Capital Markets Positive
2014-10-30 Reiterated Rating BMO Capital Markets Market Perform
2014-09-04 Initiated Coverage Credit Suisse Underperform
2014-09-04 Initiated Coverage Credit Suisse Group AG Underperform
2014-08-07 Reiterated WallachBeth Buy $9 to $8
2014-08-07 Lower Price Target WallachBeth Capital Buy $9.00 to $8.00
2014-04-24 Initiated Coverage Wells Fargo & Co. Market Perform
2014-04-24 Initiated Coverage Wells Fargo Market Perform
2013-11-15 Initiated WallachBeth Buy $9
2013-11-15 Initiated Coverage WallachBeth Capital Buy $9.00
2013-11-11 Reiterated Rating Leerink Swann Outperform $12.00
2013-11-11 Reiterated Rating Jefferies Group Buy $12.00
2013-10-16 Reiterated Rating Needham & Company LLC Hold
2013-10-03 Initiated Cowen Market Perform $4.50
2013-10-03 Initiated Coverage Cowen and Company Market Perform $4.50
2013-09-30 Lower Price Target Credit Suisse Underperform $5.00 to $4.00
2010-10-25 Reiterated Barclays Capital Underweight $3 to $2
2010-09-20 Reiterated UBS Neutral $7 to $2
2010-09-17 Downgrade Davenport Buy to Neutral
2010-09-14 Downgrade Barclays Capital Equal Weight to Underweight $4 to $3
2010-08-23 Reiterated UBS Neutral $3.50 to $7
2010-07-16 Downgrade Rodman & Renshaw Mkt Perform to Mkt Underperform $1
2010-07-02 Reiterated UBS Buy $40 to $38
2010-02-04 Upgrade Rodman & Renshaw Mkt Underperform to Mkt Perform
2009-12-17 Initiated Jefferies & Co Hold $4
2009-09-21 Downgrade Leerink Swann Outperform to Mkt Perform $6
2009-09-18 Downgrade Rodman & Renshaw Mkt Perform to Mkt Underperform $3
2009-09-15 Downgrade Rodman & Renshaw Mkt Outperform to Mkt Perform
2009-08-18 Initiated JMP Securities Mkt Perform
2009-06-24 Initiated Rodman & Renshaw Mkt Outperform $9
2009-03-16 Downgrade Canaccord Adams Hold to Sell
2008-12-10 Reiterated UBS Buy $8 to $6
2016-05-10 Reiterated Rating Wells Fargo Hold
2016-05-10 Reiterated Rating Wells Fargo & Co. Hold
2016-03-02 Reiterated Rating Piper Jaffray Buy
2016-03-02 Reiterated Rating Piper Jaffray Cos. Buy
2016-03-01 Reiterated Rating RBC Capital Sector Perform $2.00 to $1.50

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
LIEF JACK Chairman, President and CEO 0.28%  (622189) ARNA / MSTX /
BEHAN DOMINIC P SVP & Chief Scientific Officer 0.23%  (508000) ARNA /
HIXSON HARRY F JR 0.07%  (148405) ARNA / SQNM /
BELCHER DONALD D 0.06%  (134257) ARNA /
SCHNEIDER PHILLIP M 0.04%  (94257) ARNA / ASPX /
BICE SCOTT H 0.04%  (89157) ARNA /
White Christine Anna 0.04%  (85529) ARNA / MEIP /
WOODS RANDALL E 0.04%  (85257) ARNA /
Nova Tina Susan 0.04%  (84257) ADMP / ARNA / NSTG / VCYT /
HOFFMAN ROBERT VP, Finance and CFO 0.03%  (58074) ARNA / CBMX / HRTX / TELK /
Munshi Amit President and CEO 0.02%  (51875) ARNA / EPRS / RTGN /
Audet Craig Michael SVP, Opn & Head Glob Reg Afrs 0.02%  (50000) ARNA /
SHANAHAN WILLIAM R JR VP and Chief Medical Officer 0.02%  (50000) ANTH / ARNA /
SPECTOR STEVEN W SVP, General Counsel & Sec 0.01%  (19690) ARNA /

Comments